Potential Predictors for Serofast State after Treatment among HIV-Negative Persons with Syphilis in China: A Systematic Review and Meta-Analysis

*Jiabi QIN1, 2, *Tubao YANG3, Hua WANG1, Tiejian FENG4, Xiaoying LIU5

1. Division of Medical Genetics, Maternal and Child Health Hospital of Hunan Province, Hunan, China
2. Skate Key Laboratory of Medical Genetics, Central South University, Hunan, China
3. Dept. of Epidemiology and Health Statistics, School of Public Health, Central South University, Hunan, China
4. Dept. of Dermatology and Venereal Disease, Shenzhen Center for Chronic Disease Control and Prevention, Shenzhen, China
5. Caimao Hospital of Hunan Province, Hunan, China

*Corresponding Author: Email: qinjiabi123@163.com, yangtb@xysm.net

(Received 04 Aug 2014; accepted 11 Dec 2014)

Abstract

Background: Several studies have been conducted in China in order to investigate the potential predictors of serofast state after treatment among syphilitic patients. However, there is a remarkable diversity among the results. This meta-analysis was conducted to assess potential predictors of serofast among syphilitic patients in China.

Methods: International and national electronic databases were searched up to September 2013. Reference lists of retrieved articles were also reviewed. Cohort or case-control studies addressing risk factors of serofast among syphilitic patients were included in this study.

Results: We assessed 27 separate studies involving overall 6682 HIV-negative participants with syphilis of which 1962 remained in the serofast state. The serofast was positively associated with older age (P_trend=0.001), female (summary risk ratio [sRR]=1.50, 95%CI:1.34-1.68), latent syphilis (sRRlatent vs primary=3.17, 95%CI: 2.66-3.77; sRRlatent vs secondary=2.00, 95%CI: 1.48-2.69) as well as non-penicillin treatment (sRR =2.99, 95%CI:2.45-3.67), but negatively associated with higher baseline titers (sRR>1:32 vs ≤1:32=0.63, 95%CI: 0.54-0.75). Compared with healthy group and serological cure group, respectively, the levels of CD4 (+), IL-2, and IL-6 among serofast patients were decreased (standardized mean difference [SMD]<0, P<0.05), but the levels of CD8 (+) and IL-10 were increased (SMD>0, P<0.05). Some studies also hinted the serofast was associated with subtypes i of treponema pallidum (TP) repeat gene (RRi vs d=4.67,95%CI: 1.31-16.69) and TP occult infection.

Conclusion: The age, gender, stage of infection, baseline titers, treatment drug, cellular immune suppression and disorders, TP occult infection and subtypes i of TP repeat gene should be considered as important predictors of serofast. However, until now the definition and mechanism of serofast has still been not clear.

Keywords: Syphilis, Serofast, T-lymphocyte subset, Interleukin, China, Meta-analysis

Introduction

Syphilis has been a major cause of mortality and morbidity for around 500 years (1). The World Health Organization (WHO) estimates that 12 million new cases of syphilis occur each year (2, 3). In Chinese history, syphilis had been eradicated over a period in 1960s, but by the late 1990s, China’s reported syphilis cases were rising by about 30% per year (4). The reported incidence of syphilis more than tripled between 2005 and 2011, to 32.0 cases per 100 000 people. This increasing
trend was continuously observed in 2012 (5, 6). Facing the continually increasing epidemic of syphilis in China, the government has recognized that enhanced efforts are needed to respond to the epidemic. Specifically, in 2010, the China’s Ministry of Health (MOH) officially launched the first national program specially and directly aimed at controlling syphilis: the National Program for Prevention and Control of Syphilis in China (2010–2020)(7). However, the spread of syphilis transmission seem not to be prevented actually. Worriedly, a new problem of the persistent positive serological reaction after treatment among syphilitic patients is coming with the spread of syphilis, which is bound to bring about new difficulties for prevention of syphilis transmission. Syphilis management requires serological monitoring after therapy (8-12). “Not all patients achieve serological reversal after the recommended treatment; some patients demonstrate a persistent positive serological reaction that was quite disconcerting for both the physician and patient” (13). It remains unclear whether the persistent positive serological reaction indicates persistent foci of spirochetes or progressive syphilitic lesions or whether it reflects the persistence of regain in the circulating blood following anti-syphilitic therapy. For these reasons, a discussion about the serological response after the recommended therapy is more than justified. In China, in a substantial proportion(10.0% for primary syphilis, 17.5% for secondary syphilis, and 40.5% for latent syphilis) of patients with syphilis, nontreponemal titers neither increase nor decrease 4-fold after treatment and are referred to as being “serofast”(14-18). Until now, the factors that predict the serological response after the recommended therapy among syphilitic patients have not yet been thoroughly studied. A clear understanding of predictors is important to define interventions in every community. With recently accumulating evidence, our goal, therefore, was to summarize factors associated with serofast state of HIV-negative patients with syphilis in China by conducting a meta-analysis of published studies, which serves to guide clinicians regarding the identification of patients who may become serofast after therapy without clear evidence of treatment failure, and develop the optimal management program of serofast patients.

Methods

Literature search
We attempted to report this meta-analysis in accordance with the Meta-Analysis of Observational Studies in Epidemiology guidelines (19). We used and combined the following keywords: “(Serofast OR Seroresistance OR Serum fixed OR Serological cure OR Serological response) AND Syphilis AND China”. We searched both international and national electronic databases as follows: PubMed (January 1950 to September 2013), Google Scholar (January 1950 to September 2013), Chinese National Knowledge Infrastructure (CNKI) (January 1994 to September 2013), Chinese Scientific Journals Fulltext Database (CQPVIP)(January 1989 to September 2013), China Biology Medicine disc(CBMdisc)(January 1978 to September 2013), and Wanfang Data(January 1998 to September 2013). We also scanned the reference lists of all included studies for additional references. The grey literatures and conference abstracts were not searched. When reported data were not sufficient for estimation of desired comparisons, we contacted study authors.

Selection criteria
We first performed an initial screening of titles or abstracts. A second screening was based on full-text review. Studies were considered eligible for inclusion if they met the following criteria: 1) the study assessed the risk factors of serofast; 2) the study was published in Chinese or English language; 3) study participants were Chinese populations with syphilis but without HIV infection; 4) definition of serofast was clear; 5) all syphilitic patients received recommended therapy according to CDC guidelines(8) before diagnosed as serofast; 6) the exposure of interest was clinical characteristics, the levels of T-lymphocyte subset and NK cells in the peripheral blood, and the levels of interleukin and interferon in the serum; 7) the outcome of interest was serofast; 8) corresponding data were...
provided; 9) the study design was a cohort or case-control study. We excluded review papers, non-peer-reviewed local/government reports, conference abstract and presentation in the present study. Multiple papers from the same center and/or authors were analyzed to determine whether the most recent publication was an accumulation, which included cases, reported in earlier publications. If this was evident from our review, then we used only the most recent publication. We also assessed potential studies to ensure that there was no duplication of case series.

**Group definitions and measure of exposure**

After recommended therapy (non—penicillin-allergic participants were given 3 injections of 2.4 million units of benzathine penicillin at weekly intervals; penicillin—allergic participants were given doxycycline or azithromycin or erythromycin), syphilis patients were considered to be in a serofast state if their nontreponemal antibodies test remained positive and the titres neither increased nor decreased by at least four-fold (two dilutions) (9, 10). Syphilis patients whose clinical manifestations disappeared and whose nontreponemal antibodies titers became negative or decreased by four-fold (two dilutions) were regarded as achieving a serological cure (9, 10). Health group consisted of populations who went to the hospital to donate blood or seek a physical examination. They were not infected with syphilis and HIV. The Flow cytometry was used to detect the levels of T-lymphocyte subset and NK cells in the peripheral blood among health group, serofast group and serological cure group. The Enzyme linked immunosorbent assay (ELISA) was also used to detect the levels of Interleukin and interferon in the serum among healthy group, serofast group and serological cure group.

**Data extraction and quality assessment**

Two independent reviewers (QJB and YTB) extracted data and assessed study quality. Any disagreements were resolved through discussion among the authors until consensus was reached. Data extraction was then performed using a standardized data-collection form. For cohort studies, the following data were extracted: first author and year of publication; study location; study design/period; duration of follow-up; study population; exposure and outcome; methods of data collection; and comment. For case-control studies, the following data were extracted: first author and year of publication; study location; study design/period; case group/sample size; control group/sample size; exposure; measure of exposure; and comment.

We adapted the principles of the Newcastle-Ottawa-Scale (NOS) to assess the risk of bias in the included studies (20). In statistics, the scale is a tool used for assessing the quality of non-randomized studies included in a systematic review and/or meta-analysis. Using the tool, each study is judged on eight items, categorized into three groups: the selection of the study groups; the comparability of the groups; and the ascertainment of outcome or exposure. Stars awarded for each quality item serve as a quick visual assessment. Stars are awarded such that the highest quality studies are awarded up to nine stars. When the study gains at least six stars, it is considered of low-risk of bias (21). We only included studies with low-risk of bias.

**Statistical analysis**

The summary risk ratio (sRR) and standardized mean difference (SMD), respectively, were used for qualitative data and quantitative data to measure of the association between serofast and its potential risk factors, and odd ratios and incidence rate ratios were directly considered as RRs. Homogeneity of effect size across studies was tested by using the Q statistics at the $P<0.10$ level of significance. The $I^2$ statistic, which is a quantitative measure of inconsistency across studies, was also calculated (significance level at $I^2>50\%$) (22). sRR or SMD and their corresponding 95%CI were calculated using either fixed-effects models or, in the presence of heterogeneity, random-effects models (23). Sensitivity analysis was conducted to explore possible explanations for heterogeneity and examine the influence of various exclusion criteria on the overall risk estimate. We also investigated the influence of a single study on the overall risk esti-
mate by omitting one study in each turn. Potential publication bias was assessed by visual inspection of the Begg’s funnel plots, Begg’s rank correlation test, Egger’s linear regression test, and Macaskill’s test (24). Begg’s rank correlation test, Egger’s linear regression test, and Macaskill’s test were performed by using SAS version 8.2 (SAS Institute, Cary, NC, USA). Other analyses were performed by Review Manager-version 5.0. A P-value <0.05 was considered statistically significant, except where otherwise specified.

Results

Study selection and study quality assessment

Overall, 1245 studies were identified, of which 402 potentially relevant articles were selected for further screening, and eventually 27 studies (10, 11, 14, 17, 18, 25–46) involving 6682 HIV-negative participants with Syphilis in China were considered eligible for inclusion (Fig. 1). The extracted data involving 11 cohort studies and 16 case-control studies and published between 2005 and 2013 were shown in Table 1. The shortest length from first treatment to diagnosis of serofast after treatment was more than 6 months, and the length in 92.6% (25/27) of eligible studies was ≥ one year. In all studies, blood sample were tested for HIV and syphilis. Some studies comprising participants with positive HIV test have been excluded. In included studies, participants with serum positive for both Treponema pallidum particle assay (TPPA) and rapid plasma regain (RPR) or toluidine red unheated serum test (TRUST) were determined to be currently infected with syphilis. RPR or TRUST titers were used to evaluate serological response at 6 and 12 months after treatment for primary and secondary syphilis and, additionally, at 24 months for latent syphilis.

Fig. 1: Study identification flowchart
Table 1: Characteristics of 27 included studies

| Reference number | Location | Study design/period | Duration of follow-up | Study population | Exposure | Outcomes | Methods of data collection | Comment |
|------------------|----------|---------------------|-----------------------|------------------|----------|----------|---------------------------|---------|
| 17               | Guangzhou | Retrospective cohort/1994-2003 | 2 years | 423 patients | Age, gender, stage of syphilis and initial titers of non-treponema antibodies | Serofast status and serological cure | Medical records | In this study, the clinical data of patients with syphilis in the recent ten years were reviewed, the incidence and the duration of occurrence of serofast, the relationship between serofast and age, sex, stage of disease, RPR initial titer of the patients were analyzed respectively by multiple regression. |
| 18               | Beijing  | Retrospective cohort/2001-2005 | 2 years | 131 patients | Age, gender, initial titers of non-treponema antibodies, stage of syphilis and treatment | Serofast status and serological cure | Medical records | In this study, the incidence of serofast was investigated and the correlation between serofast and factors including age, gender, initial titer, disease course, and medications were analyzed. |
| 25               | Zhangzhou | Retrospective cohort/2002-2006 | 2 years | 224 patients | Stage of syphilis | Serofast status and serological cure | Medical records | In this study, based on 5 years clinical data, the incidence of serofast was investigated and the correlation between serofast and stage of syphilis was analyzed. |
| 26               | Liuzhou  | Retrospective cohort/2002-2006 | 2 years | 318 patients | Stage of syphilis | Serofast status and serological cure | Medical records | In this study, the incidences of serofast based on stage of syphilis and the time when serofast were formed were analyzed. |
| 27               | Beijing  | Retrospective cohort/unknown | Unknown | 172 patients | Stage of syphilis, treatment, T-lymphocyte subset and NK cells in the peripheral blood | Serofast status and serological cure | Medical records and Flow cytometry | In this study, the correlation between serofast and related factors including initial titer of RPR, disease course, and medication. Flow cytometry was used to analyze T-lymphocyte subset and NK cells in the peripheral blood of untreated syphilitic patients, syphilitic patients whose serology turned negative after treatment, serofast patients, and healthy controls. |
| 28               | Guangzhou | Retrospective cohort/2005-2009 | >2 years | 366 patients | Stage of syphilis and treatment | Serofast status and serological cure | Medical records | In this study, the incidences of serofast based on stage of syphilis, treatment factors, and the time when serofast were formed were analyzed. |
| 29               | Guangzhou | Prospective cohort/2008-2009 | 1 years | 102 patients | Subtypes of Treponema pallidum repeat(tpr) gene | Serofast status and serological cure | Medical records and Polymerase Chain Reaction(PCR) | In this study, specimens of confirmed patients with untreated early syphilis were collected by multiple centers cooperation. Treponema pallidum basic membrane protein (bmp) genes were screened from these specimens by nested PCR. After standard treatment, the relationship between the change of serum TRUST titer of the patients and the subtypes of tpr gene were analyzed. |
| 30               | Shanghai | Prospective cohort/2002-2009 | >2 years | 420 patients | Stage of syphilis | Serofast status and serological cure | Medical records | In this study, the incidences of serofast based on stage of syphilis and the association between serofast and stage of syphilis were analyzed. |
| 14               | Xiamen   | Prospective cohort/2005-2009 | 1 year | 1308 patients | Stage of syphilis and treponema pallidum(TP) IgM antibody | Serofast status and serological cure | Medical records | In this study, TP-IgM was detected with FTA-Abs and TPPA. Syphilitic patients were divided into experimental groups according to the results of TRUST and TPPA. Relationship between serofast, stage of syphilis, and TP-IgM were analyzed. |
| 11               | Beijing  | Prospective cohort/2000-2010 | >6 months | 501 patients | Demographic characteristics, clinical characteristics, and behavior characteristics | Serofast status and serological cure | Medical records | In this study, analysis of factors determining the serological response to treatment was performed in HIV-negative patients with early syphilis, using demographic characteristics, clinical characteristics, and behavior characteristics. |
| 10               | Xiamen   | Prospective cohort/2005-2010 | 1 year | 1327 patients | Age, gender, initial titers of non-treponema antibodies, and stage of syphilis | Serofast status and serological cure | Medical records | In this study, the incidence of serofast was investigated and the correlation between serofast and factors including age, gender, initial titer, and disease course were analyzed. |

**Abbreviation:** PCR= polymerase chain reaction; FTA-Abs= fluorescent treponemal antibody absorption; TPPA= Treponema pallidum particle agglutination; TP= Treponema Pallidum

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
Table 1: Continued

| Reference number | Location  | Study design/period | Case group/sample size | Control group/sample size | Exposure | Measure of exposure | Comment |
|------------------|-----------|---------------------|------------------------|---------------------------|----------|--------------------|---------|
| 31               | Guangzhou| HCC/unknown         | Serofast group/32 cases | Healthy group/30 cases    | T-lymphocyte subset and NK cells in the peripheral blood | Flow cytometry | In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood between serofast group and healthy group were compared. |
| 32               | Guangzhou| HCC/unknown         | Serofast group/38 cases | Healthy group/23 cases    | T-lymphocyte subset and NK cells in the peripheral blood | Flow cytometry | In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood between serofast group and healthy group were compared. |
| 33               | Shenzhen | HCC/unknown         | Serofast group/30 cases | Healthy group/30 cases    | T-lymphocyte subset | Flow cytometry | In this study, the levels of T-lymphocyte subset in the peripheral blood between serofast group and healthy group were compared. |
| 34               | Nanchang | HCC/2004-2006       | Serofast group/20 cases | Healthy group/20 cases; Serological cure/20 cases | The levels of IFN-\(\gamma\) and IL-10 in the serum | ELISA | In this study, the levels of T-lymphocyte subset in the peripheral blood between serofast patients and syphilitic patients whose serology turned negative after treatment, and healthy controls were compared, respectively. |
| 35               | Guangzhou| HCC/2001-2006       | Serofast group/58 cases | Serological cure/60 cases | T-lymphocyte subset in the peripheral blood | Flow cytometry | In this study, the levels of T-lymphocyte subset in the peripheral blood between serofast patients and healthy group were compared. |
| 36               | 2 cities *| HCC/2003-2006       | Serofast group/38 cases | Healthy group/23 cases | The levels of IL-12 and IL-10 in the serum | ELISA | In this study, the levels of IL-12 and IL-10 in the serum of serofast patients and healthy group were compared. |
| 37               | Chengdu  | HCC/2005-2007       | Serofast group/20 cases | Healthy group/30 cases; Serological cure/30 cases | T-lymphocyte subset and NK cells in the peripheral blood | Flow cytometry | In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared. |
| 38               | Chongqing| HCC/2004-2006       | Serofast group/20 cases | Healthy group/30 cases; Serological cure/20 cases | The levels of IL-2 and IL-10 in the serum | ELISA | In this study, the levels of IL-2 and IL-10 in the serum of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared, respectively. |
| 39               | Suzhou   | HCC/2008-2009       | Serofast group/23 cases | Healthy group/20 cases; Serological cure/20 cases | T-lymphocyte subset and NK cells in the peripheral blood | Flow cytometry | In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared. |
| 40               | Hefei    | HCC/2005-2009       | Serofast group/25 cases | Healthy group/20 cases; | T-lymphocyte subset and NK cells in the peripheral blood | Flow cytometry | In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood of serofast patients and healthy controls were compared. |
| 41               | Dongguan | HCC/2009-2010       | Serofast group/18 cases | Healthy group/18 cases; | CD4(+)CD25(+) regulatory T cells in the peripheral blood and IL-17 in the serum | Flow cytometry and ELISA | In this study, the levels of CD4(+)CD25(+) regulatory T cells in the peripheral blood and IL-17 in the serum of serofast patients, and healthy controls were compared. |
| 42               | Shenzhen | HCC/2010-2011       | Serofast group/60 cases | Healthy group/63 cases; Serological cure/61 cases | T-lymphocyte subset in the peripheral blood, and IL-17 and IL-23 in the serum | Flow cytometry and ELISA | In this study, the levels of T-lymphocyte subset in the peripheral blood, and IL-17 and IL-23 in the serum of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared. |
| 43               | Jieyang  | HCC/unknown          | Serofast group/112 cases | Healthy group/58 cases; Serological cure/155 cases | CD4(+)CD25(+) regulatory T cells in the peripheral blood and IL-10, IL-6 and IFN-\(\gamma\) in the serum | Flow cytometry and ELISA | In this study, the levels of CD4(+)CD25(+) regulatory T cells in the peripheral blood and IL-0, IL-6 and IFN-\(\gamma\) in the serum of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared. |
| 44               | Nanning  | HCC/2007-2011       | Serofast group/32 cases | Healthy group/22 cases | The levels of IL-2, IL-4, IL-10, and IL-12 in the serum | ELISA | In this study, the levels of IL-2, IL-4, IL-10, and IL-12 in the serum of serofast patients, and healthy controls were compared. |
| 45               | Nanning  | HCC/2007-2011       | Serofast group/32 cases | Healthy group/11 cases | T-lymphocyte subset and NK cells in the peripheral blood | Flow cytometry | In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood of serofast patients, and healthy controls were compared. |
| 46               | Hanchuan | HCC/2007-2011       | Serofast group/46 cases | Healthy group/22 cases | T-lymphocyte subset and NK cells in the peripheral blood | Flow cytometry | In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood of serofast patients, and healthy controls were compared. |

Abbreviation: HCC= hospital-based case-control study; ELISA= enzyme linked immunosorbent assay; * 2 cities include Zhangjiakou, and Guangzhou.

Available at:  [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
In two studies (11, 39), serological cure was defined as either negative nontreponemal antibody test results or a ≥4-fold (2 dilution) decrease in titer after treatment. In remaining studies, serological cure was defined as negative nontreponemal antibodies test results after treatment. For all included studies, serofast status was defined as either no change in titer or a ≤2-fold (1 dilution) titer decrease or increase from baseline, and the titer range at the diagnosis of serofast status was from 1:1 to 1:8. All included studies scored at least six stars according to NOS score system (Table 2), so they were considered of low-risk of bias.

Table 2: Star template of cohort and case-control studies based on NOS assessment
Clinical characteristics of patients with syphilis associated with serofast

Trend test showed syphilitic patients with an older age were prone to be serofast after treatment ($P_{\text{trend}}=0.001$). Female patients (sRR = 1.50, 95%CI: 1.34 to 1.68), latent syphilis (sRR$_{\text{latent vs primary}}$ = 3.17, 95%CI: 2.66 to 3.77; sRR$_{\text{latent vs secondary}}$ = 2.00, 95%CI: 1.48 to 2.69), and using non-penicillin treatment (sRR = 2.99, 95%CI: 2.45 to 3.67) also increased the risk of serofast, but high baseline titers (>1:32) of nontreponemal antibodies (sRR = 0.63, 95%CI: 0.54 to 0.75) decreased the risk of serofast (Table 3). There was no evidence of heterogeneity except for stage of syphilis (all $P$ values $\leq 0.0003$; $I^2$ = 71 to 84%). One study (29) showed the TP repeat gene subtype i increased the risk of serofast, when it was compared with subtype d (RR = 4.67, 95%CI: 1.31 to 16.69) and subtype e (RR = 5.00, 95%CI: 0.33 to 75.11), respectively. In one study (14), TP-IgM antibody between serofast patients and syphilitic patients whose serology turned negative after treatment (i.e., serological cure) was detected by fluorescent treponemal antibody absorption (FTA-Abs) and TPPA, and the results showed positive FTA-Abs-TP-IgM (RR = 3.27, 95%CI: 2.89 to 3.69) and TPPA-TP-IgM (RR = 3.26, 95%CI: 2.89 to 3.68) test increased the risk of serofast, which implied the serofast was associated with occult TP infection.

Table 3: Meta-analysis of association between clinical features of patients with syphilis and serofast status

| Clinical features | Number of studies | Participants | Statistical methods | RR(95%CI) | Heterogeneity | $I^2$ |
|-------------------|-------------------|-------------|---------------------|-----------|--------------|------|
| Age(year)         |                   |             |                     |           |              |      |
| $\geq 40$ vs $\leq 24$ | 3                 | 963         | RR (M-H,FEM, 95%CI) | 2.53(1.53,4.19)* | 4.03  | 0.57 | 0%  |
| $\geq 40$ vs 25-39 | 3                 | 1606        | RR (M-H,FEM, 95%CI) | 1.99(1.32,3.01)* | 3.29  | 0.73 | 0%  |
| gender(female vs male) | 7                 | 3251        | RR (M-H,FEM, 95%CI) | 1.50(1.34,1.68)* | 3.38  | 0.76 | 0%  |
| initial titers of non-treponema antibodies (>1:32 vs <=1:32) | 4                 | 2552        | RR (M-H,FEM, 95%CI) | 0.63(0.54,0.75)* | 0.67  | 0.71 | 0%  |
| Stage of syphilis |                   |             |                     |           |              |      |
| Latent vs primary | 11                | 3103        | RR (M-H,FEM, 95%CI) | 3.17(2.66,3.77)* | 15.64 | 0.11 | 36% |
| Latent vs secondary | 10               | 3747        | RR (M-H,REM, 95%CI) | 2.00(1.48,2.69)* | 55.51 | <0.00001 | 84% |
| Secondary vs primary | 10               | 3009        | RR (M-H,REM, 95%CI) | 1.71(1.14,2.57)* | 30.93 | 0.0003 | 71% |
| Treatment(non-penicillin vs penicillin) | 3                 | 669         | RR (M-H,FEM, 95%CI) | 2.99(2.45,3.67)* | 0.72  | 0.70 | 0%  |
| Subtypes of TP repeat gene |           |             |                     |           |              |      |
| Subtype i vs subtype d | 1                | 36          | RR (M-H,FEM, 95%CI) | 4.67(1.31,16.69)* | —     | —    | —   |
| Subtype i vs subtype e | 1                | 12          | RR (M-H,FEM, 95%CI) | 5.00(0.33,75.11) | —     | —    | —   |
| TP IgM antibody |                   |             |                     |           |              |      |
| FTA-Abs(positive vs negative) | 1            | 1208        | RR (M-H,FEM, 95%CI) | 3.27(2.89,3.69)* | —     | —    | —   |
| TPPA(positive vs negative) | 1            | 1208        | RR (M-H,FEM, 95%CI) | 3.26(2.89,3.68)* | —     | —    | —   |

Abbreviation: TP = treponema pallidum; FTA-Abs = fluorescent treponemal antibody absorption; TPPA = treponema pallidum particle agglutination

*Statistically significant ($P<0.05$)
T-lymphocyte subset and NK cells in the peripheral blood associated with serofast

Present study showed that the serofast was associated with the levels of T-lymphocyte subset in the peripheral blood (Table 4). Compared with healthy group, the proportions of CD3(+) (SMD=-0.52, 95% CI: -0.71 to -0.34), CD4(+) (SMD=-0.67, 95% CI: -1.11 to -0.23), Th1 cells (SMD=-1.26, 95% CI: -2.00 to -0.52) and Th1/Th2 (SMD=-1.52, 95% CI: -2.29 to -0.76) among serofast patients were decreased, but CD8(+) (SMD=0.58, 95% CI: 0.41 to 0.76), CD4(+)CD25(+) regulatory T cells (SMD=1.92, 95% CI: 1.57 to 2.26), and Th2 cells (SMD=0.91, 95% CI: 0.20 to 1.63) were increased. When compared with serological cure group, the CD4 (+) (SMD=-0.70, 95% CI: -1.26 to -0.14) among serofast patients was also decreased, but CD8 (+) (SMD=0.82, 95% CI: 0.09 to 1.56) and CD4 (+) CD25 (+) regulatory T cells (SMD=2.12, 95% CI: 1.82 to 2.42) were increased. When serological cure group was compared with healthy group, there were no significant difference for the levels of CD3 (SMD=-0.09, 95% CI: -0.38 to 0.20), CD4 (+) (SMD=-0.04, 95% CI: -0.33 to 0.24) and CD8(+) (SMD=-0.18, 95% CI: -0.66 to 0.30). Substantial heterogeneity was observed (all P values ≤ 0.006; I²=57 to 94%).

Table 4: Meta-analysis of association between T-lymphocyte subset and NK cells in the peripheral blood and serofast status

| T-lymphocyte subset and NK cells | Number of studies | Participants | Statistical methods | SMD(95%CI) | Heterogeneity | P | I² |
|----------------------------------|------------------|-------------|---------------------|------------|--------------|---|----|
| CD3(+)                           |                  |             |                     |            |              |   |     |
| Serofast group vs healthy group  | 8                | 512         | SMD (IV, REM, 95% CI) | -0.52(-0.71,-0.34)* | 50.08 | <0.00001 | 86% |
| Serofast group vs serological cure| 4                | 332         | SMD (IV, REM, 95% CI) | -0.58(-1.21,0.06) | 22.03 | <0.00001 | 86% |
| Serological cure vs healthy group | 2                | 184         | SMD (IV, REM, 95% CI) | -0.09(-0.38,0.20) | 0.17  | 0.68    | 0  |
| CD4(+)                           |                  |             |                     |            |              |   |     |
| Serofast group vs healthy group  | 9                | 555         | SMD (IV, REM, 95% CI) | -0.67(-1.11,-0.23)* | 46.09 | <0.00001 | 83% |
| Serofast group vs serological cure| 4                | 332         | SMD (IV, REM, 95% CI) | -0.70(-1.26,-0.14)* | 16.93 | 0.006   | 57% |
| Serological cure vs healthy group | 2                | 184         | SMD (IV, REM, 95% CI) | -0.04(-0.33,0.24) | 0.14  | 0.71    | 0  |
| CD8(+)                           |                  |             |                     |            |              |   |     |
| Serofast group vs healthy group  | 9                | 555         | SMD (IV, REM, 95% CI) | 0.58(0.41,0.76)* | 12.31 | 0.14    | 35% |
| Serofast group vs serological cure| 4                | 332         | SMD (IV, REM, 95% CI) | 0.82(0.09,1.56)* | 28.09 | <0.00001 | 89% |
| Serological cure vs healthy group | 2                | 184         | SMD (IV, REM, 95% CI) | -0.18(-0.66,0.30) | 2.43  | 0.12    | 59% |
| CD4(+)/CD8(+)                    |                  |             |                     |            |              |   |     |
| Serofast group vs healthy group  | 4                | 199         | SMD (IV, REM, 95% CI) | -0.71(-1.53,0.10) | 20.35 | 0.0001  | 85% |
| Serofast group vs serological cure| 1                | 43          | SMD (IV, REM, 95% CI) | 0.33(0.28,0.93)  |       |         |    |
| Serological cure vs healthy group | 1                | 40          | SMD (IV, REM, 95% CI) | -1.89(-2.65,-1.13)* |     |         |    |
| CD4(+)/CD25(+) regulatory T cells |                  |             |                     |            |              |   |     |
| Serofast group vs healthy group  | 2                | 206         | SMD (IV, REM, 95% CI) | 1.92(1.57,2.26)* | 0.12  | 0.73    | 0  |
| Serofast group vs serological cure| 1                | 267         | SMD (IV, REM, 95% CI) | 2.12(1.82,2.42)* |       |         |    |
| NK cell                          |                  |             |                     |            |              |   |     |
| Serofast group vs healthy group  | 7                | 372         | SMD (IV, REM, 95% CI) | -0.85(-1.80,0.10) | 97.40 | <0.00001 | 94% |
| Serofast group vs serological cure| 2                | 93          | SMD (IV, REM, 95% CI) | -0.13(-0.54,0.29) | 0     | 1       | 0  |
| Serological cure vs healthy group | 1                | 60          | SMD (IV, REM, 95% CI) | 0.48(-0.04,0.99) |       |         |    |
| Th1 cell                         |                  |             |                     |            |              |   |     |
| Serofast group vs healthy group  | 1                | 43          | SMD (IV, REM, 95% CI) | -1.26(-2.00,-0.52) |     |         |    |
| Th2 cell                         |                  |             |                     |            |              |   |     |
| Serofast group vs healthy group  | 1                | 43          | SMD (IV, REM, 95% CI) | 0.91(0.20,1.63)* |       |         |    |
| Th1/Th2                          |                  |             |                     |            |              |   |     |
| Serofast group vs healthy group  | 1                | 43          | SMD (IV, REM, 95% CI) | -1.52(-2.29,-0.76)* |     |         |    |

*Statistically significant (P<0.05)

Interleukin and interferon in the serum associated with serofast

Finding from our study demonstrated that the serofast was associated with the levels of interleukin in the serum (Table 5). Compared with healthy group, the levels of IL-12 (SMD=-1.56 95%CI: -1.99 to -1.13), IL-2(SMD=1.06, 95%CI: -1.66 to -0.45), IL-6(SMD= -1.09, 95%CI: -1.42 to -0.75), and IFN-γ(SMD=-1.29, 95%CI: -2.31 to -0.26) among serofast patients was decreased, but IL-
10(SMD=1.68, 95%CI: 0.75 to 2.60) and IL-4(SMD=0.75, 95%CI: 0.19 to 1.32) were increased. When serofast patients were compared with serological cure group, the levels of IL-2(SMD=−1.03, 95%CI: -1.70 to -0.37) and IL-6(SMD=−1.00, 95%CI: −1.26 to -0.74) was also declined, but IL-10(SMD=2.23, 95%CI: 0.25 to 4.21) was elevated. For the levels of IL-10(SMD=0.11, 95%CI: -0.13 to 0.36), IL-2(SMD=−0.07, 95%CI: -0.63 to 0.50), IL-17(SMD=−0.01, 95%CI: -0.37 to 0.34), IL-23(SMD=−0.02, 95%CI: -0.37 to 0.33), IL-6(SMD=0.19, 95%CI: -0.11 to 0.50), and IFN-r(SMD=0.14, 95%CI: -0.14 to 0.41), there were no significantly statistical difference between serological cure group and healthy group. Substantial heterogeneity was found (all P values ≤ 0.006; I²=87 to 97%).

Table 5: Meta-analysis of association between interleukin and interferon in the serum and serofast status

| interleukin and interferon | Number of studies | Participants | Statistical methods | SMD(95%CI) | Heterogeneity | I² |
|----------------------------|-------------------|--------------|---------------------|------------|---------------|---|
| IL-10                      |                   |              |                     |            |               |   |
| Serofast group vs healthy group | 5                 | 375          | SMD(IV, REM, 95% CI) | 1.68(0.75, 2.60)* | 50.53          | <0.00001 | 92%  |
| Serofast group vs serological cure | 3                | 347          | SMD(IV, REM, 95% CI) | 2.23 (0.25, 4.21)* | 67.12          | <0.00001 | 97%  |
| Serological cure vs healthy group | 3                | 303          | SMD(IV, FEM, 95% CI) | 0.11(-0.03, 0.36) | 1.55           | 0.46       | 0    |
| IL-17                      |                   |              |                     |            |               |   |
| Serofast group vs healthy group | 2                | 159          | SMD (IV, FEM, 95% CI) | -0.15 (-0.46, 0.17) | 1.72           | 0.19       | 42%  |
| Serofast group vs serological cure | 2                | 115          | SMD (IV, FEM, 95% CI) | -1.56 (-1.99, -1.13)* | 1.63           | 0.20       | 39%  |
| IL-2                       |                   |              |                     |            |               |   |
| Serofast group vs healthy group | 2                | 104          | SMD (IV, FEM, 95% CI) | -1.06 (-1.66, -0.45)* | 0.60           | 0.44       | 0    |
| Serofast group vs serological cure | 1               | 40           | SMD (IV, FEM, 95% CI) | -1.03 (-1.70, -0.37)* | —             | —         | —    |
| Serological cure vs healthy group | 1               | 50           | SMD (IV, FEM, 95% CI) | -0.07 (-0.63, 0.50) | —             | —         | —    |
| IL-17                      |                   |              |                     |            |               |   |
| Serofast group vs serological cure | 1               | 121          | SMD (IV, FEM, 95% CI) | -0.02 (-0.38, 0.33) | —             | —         | —    |
| Serological cure vs healthy group | 1               | 124          | SMD (IV, FEM, 95% CI) | -0.01 (-0.37, 0.34) | —             | —         | —    |
| IL-23                      |                   |              |                     |            |               |   |
| Serofast group vs healthy group | 1                | 123          | SMD (IV, FEM, 95% CI) | 0.14 (-0.21, 0.50) | —             | —         | —    |
| Serofast group vs serological cure | 1               | 121          | SMD (IV, FEM, 95% CI) | -0.05 (-0.41, 0.30) | —             | —         | —    |
| Serological cure vs healthy group | 1               | 124          | SMD (IV, FEM, 95% CI) | -0.02 (-0.37, 0.33) | —             | —         | —    |
| IL-6                       |                   |              |                     |            |               |   |
| Serofast group vs healthy group | 1                | 170          | SMD (IV, FEM, 95% CI) | -1.09 (-1.42, -0.75)* | —             | —         | —    |
| Serofast group vs serological cure | 1               | 267          | SMD (IV, FEM, 95% CI) | -1.00 (-1.26, -0.74)* | —             | —         | —    |
| Serological cure vs healthy group | 1               | 213          | SMD (IV, FEM, 95% CI) | 0.19 (-0.11, 0.50) | —             | —         | —    |
| IL-17                      |                   |              |                     |            |               |   |
| Serofast group vs healthy group | 1                | 54           | SMD (IV, FEM, 95% CI) | 0.75 (0.19, 1.32) | —             | —         | —    |
| IFN-γ                      |                   |              |                     |            |               |   |
| Serofast group vs healthy group | 2                | 210          | SMD (IV, REM, 95% CI) | -1.29 (-2.31, -0.26)* | 7.41           | 0.006      | 87%  |
| Serological cure vs healthy group | 2               | 307          | SMD (IV, REM, 95% CI) | -1.44 (-3.11, 0.23) | 22.36         | <0.00001   | 96%  |

*Statistically significant (P<0.05)
Publication bias
For gender (Begg’s test: Z=0.19, P=1; Egger’s test: t=0.31, P=0.77; Macaskill’s test: t=0.22, P=0.84), latent syphilis vs primary syphilis (Begg’s test: Z=0.72, P=0.47; Egger’s test: t=1.02, P=0.34; Macaskill’s test: t=0.32, P=0.76), latent syphilis vs secondary syphilis (Begg’s test: Z=0.31, P=0.76; Egger’s test: t=1.44, P=0.12; Macaskill’s test: t=1.02, P=0.21), secondary syphilis vs primary syphilis (Begg’s test: Z=0.31, P=0.75; Egger’s test: t=0.59, P=0.57; Macaskill’s test: t=1.47, P=0.19), CD3 (+) (Begg’s test: Z=1.20, P=0.22; Egger’s test: t=1.34, P=0.14; Macaskill’s test: t=1.63, P=0.12), CD4 (+) (Begg’s test: Z=0.75, P=0.45; Egger’s test: t=0.60, P=0.58; Macaskill’s test: t=0.05, P=0.96), CD8 (+) (Begg’s test: Z=0, P=1; Egger’s test: t=0.48, P=0.65; Macaskill’s test: t=0.46, P=0.67), and NK cells (Begg’s test: Z=0.75, P=0.45; Egger’s test: t=0.59, P=0.57; Macaskill’s test: t=1.02, P=0.21), Egger’s test, Begg’s test, and Macaskill’ test also indicated little evidence of publication bias (all P > 0.1).

Sensitivity analysis
Sensitivity analyses were conducted to explore potential sources of heterogeneity in the association between serofast and potential risk factors and to examine the influence of various exclusion criteria on the overall risk estimate. In our study, sensitivity analysis was performed only for these factors including ≥6 studies such as gender, stage of syphilis, CD3 (+) (only for the comparison between serofast group and healthy group), CD4 (+) (only for the comparison between serofast group and healthy group), CD8 (+) (only for the comparison between serofast group and healthy group) and NK cells (only for the comparison between serofast group and healthy group). Exclusion of two studies (11, 39) in which serological cure was defined as either negative nontreponemal antibodies test or a ≥4-fold (2 dilution) decrease in titer after treatment, but in remaining studies, serological definition was defined as negative nontreponemal antibodies test after treatment and one study (11) in which the length from first treatment to diagnosis of serofast was more than 6 months but less than one year yielded similar results. Further exclusion of any single study did not materially alter the overall estimates.

Discussion
The present study represents, to our knowledge, the first systematic evaluation to assess potential predictors that differentiate HIV-negative individuals from those without serological response by using a systematic review and meta-analysis. Our study including a large proportion of Chinese patients with syphilis (6682 HIV-negative participants infected with Syphilis) with sufficient statistical power aimed at addressing long-term clinical dilemma regarding the mechanism of serofast after treatment. Our findings may serve to guide clinicians regarding the identification of patients who may become serofast after therapy without clear evidence of treatment failure, and provide direct information for conducting targeted interventions in every community in the future, which will help to develop the optimal management program of serofast patients.

Presently, it is still not consistent for definition of the serofast (8-10, 16). Most Chinese experts think, it is reasonable that the length between first therapy and diagnosis of serofast is 12 months and 24 months for early syphilis (i.e., primary syphilis, secondary syphilis, and late syphilis (infection time > 2 years), respectively (47). Some studies also indicated if patients’ titers after treatment stay at some level (1:1 to 1:8) or have no change more than 3 months after treatment, it should be considered as serofast (47). In the present study, the shortest length from first treatment to diagnosis of serofast was more than 6 months, and the length in 92.3% of eligible studies was ≥ one year. For all of the studies, the titer range at the diagnosis of serofast was from 1:1 to 1:8.
Finding from our study showed that the serofast was positively associated with older age, female, latent syphilis as well as non-penicillin treatment, but negatively associated with higher baseline titers. Previous studies from other countries confirmed our results (9, 48, 49). Using non-penicillin, such as erythromycin and azithromycin, increased the risk of serofast, which implies that penicillin remains preferred drug of choice for treatment of syphilis. However, Sena AC (9) using data from a large, prospective, controlled trial showed the advantage that using benzathine penicillin to prevent serofast did not exist, when compared with azithromycin. It’s worth noting that one study (29) hinted that the serofast was also positively associated with subtype i of TP repeat gene. However, in this study, the sample size is small. So the association between serofast and subtypes of TP repeat gene need further research. Previous studies (50, 51) also demonstrated that TP repeat gene family has strong variability, which allows TP to evade the body’s immune destruction and leads to chronic infection of syphilis. In addition, one study also suggested that the serofast was positively associated with TP occult infection (15).

It seems that solely relying on clinical characteristics does not fully explain the mechanism of serofast. For example, previous studies(9) confirmed the relationship between the stage of infection and the baseline titer was evident in predicting treatment response, because participants with primary syphilis had a higher proportion of serological cure, whereas 43-58% of patients with secondary or early latent syphilis and baseline titers ≤1:32 were serofast at 6 months after treatment. Recently, investigators attempted to distinguish the cellular response in syphilitic patients after treatment by analyzing the levels of T-lymphocyte subset and NK cells in the peripheral blood, and Interleukin and interferon in the serum associated with serofast (27, 31-46). From the perspective of the body immune response, our study implies that the serofast was mainly associated with CD4(+) and CD8(+) cells levels in the peripheral blood, and IL-2, IL-6 and IL-10 levels in the serum, and specific performance: the levels of CD4(+), IL-2, and IL-6 are decreased, but the levels of CD8 and IL-10 are increased. Previous studies (50, 51) also suggested that serological response after treatment of syphilis was directly associated with suppression and disorders of body’ immune function. However, some studies found no differences in cell types or proportions among individuals with serofast after treatment, compared with normal controls (27). So further investigations are essential to elucidate the biological basis for the serofast state and to determine whether serofast patients should undergo continued serological monitoring, retreatment, or cerebrospinal fluid examination for TP involvement.

Potential limitations of this study should be considered. Firstly, residual confounders are always of concern in observational studies. Although most included studies adjusted for a wide range of potential confounders for serofast, we still could not exclude the possibility that other unmeasured or inadequately measured factors have confounded the true association. Secondly, there are no widely accepted standards for diagnosis of serofast, and it is unclear for the optimal time point for assessment of serological response. Therefore, the random misclassification of serofast may influence the results. Thirdly, the results have to be viewed with caution because there was significant heterogeneity (I²: from 57 to 97%). Although there was still evidence of heterogeneity, after sensitivity analyses, the result with very few changes was stable and reliable. In addition, the assessment also indicated little evidence of publication bias. So our estimates were considered reasonable. However, these estimates have to be viewed with caution because there was significant heterogeneity. Fourthly, our relatively strict inclusion criteria might have introduced selection bias. Finally, because the results of the current analysis were mainly based on data from Chinese populations, additional research in other populations is warranted to generalize the findings.

Conclusion

The present study represents, to our knowledge, the first systematic evaluation to assess potential predictors that differentiate HIV-negative individu-
uals from those without serological response, using a systematic review and meta-analysis. Although the role of potential bias and evidence of heterogeneity should be carefully evaluated, finding from our study indicated that the older age, female, lower baseline titre, latent course of infection, non-penicillin treatment, TP repeat group subtype i, TP occult infection as well as the levels of CD4 (+), CD8 (+), IL-2, IL-6 and IL-10 among HIV-negative patients with syphilis should be considered as important predictors of serofast. However, until now the definition and mechanism of serofast has still been not clear, and it is necessary for further research.

**Ethical considerations**

Ethical issues (Including plagiarism, Informed Consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

**Acknowledgements**

The authors want to thank the Fundamental Research Funds for Central South University (2012zzts029) and the Hunan Province Innovation Projects (CX2012B076) of China for their funding support. Authors also thank editors and reviewers for their suggestions. The authors declare that they have no conflicts of interest.

**References**

1. Fisman DN (2007). Syphilis resurgent in China. *Lancet*, 369:84-5.
2. Newman L, Kamb M, Hawkes S, Gomez G, Say L, Seac A, et al. (2013). Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. *PLoS Med*, 10(2):e1001396.
3. WHO (2011). Global HIV/AIDS response: Epidemiologic update and health sector progress towards universal access: Progress report. Geneva, Switzerland: World Health Organization.
4. Chen XS, Yin YP, Wang QQ, Wang BX (2013). Historical perspective of syphilis in the past 60 years in China: eliminated, forgotten, on the return. *Chin Med J (Engl)*, 126(14):2774-9.
5. National Center for STD Control (2013). 2012 Epidemiologic reports of syphilis and gonorrhea case reports in China. Available at: http://www.ncstdc.org/npfil es/201303/20130319152506703.pdf.
6. Chen XS, Wang QQ, Yin YP, Liang GJ, Jiang N, Yang LG, et al. (2012). Prevalence of syphilis infection in different tiers of female sex workers in China: implications for surveillance and interventions. *BMC Infect Dis*, 12: 84.
7. China Ministry of Health (2012). Notice of the Ministry of Health on Issuing National Program for Prevention and Control of Syphilis in China (2010-2020). Available at: http://www.gov.cn/gzdt/2010-06/21/content_1632301.htm.
8. Workowski KA, Berman SM (2010). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*, 59: 1-110.
9. Arlene C.Sena, Mark Wolff, David H.Martin, Beths E, Van Damme K, Leone P, et al. (2011). Predictors of Serological Cure and Serofast State After Treatment in HIV-Negative Persons With Early Syphilis. *Clin Infect Dis*, 53(11):1092-9.
10. Tong ML, Lin LR, Liu GL, Zhang HL, Zeng YL, Zheng WH, et al (2013). Factors associated with serological cure and the serofast state of HIV-negative patients with primary, secondary, latent, and tertiary syphilis. *PLoS One*, 8(7):e70102.
11. Li J, Wang LN, Zheng HY (2013). Predictors of serological cure and serofast state after treatment in HIV-negative patients with early syphilis in China. *Sex Transm Infect*, 89(1):69.
12. Keynan Y (2012). Predictors of serological cure after treatment of early syphilis. *Clin Infect Dis*, 54(7):1037.
13. Moore JE, Padget P (1938). The problem of seroresistant syphilis. *J Am Med Assoc*, 110: 96-100.
14. Lin L-R, Zheng W-H, Tong M-I, Fu ZG, Liu GL, Fu JG, et al. (2011). Further Evaluation of the Characteristics of Treponema Pallidum-specific IgM antibody in syphilis serofast reaction patients. *Diagn Microbiol Infect Dis*, 71: 201-207.
15. Lin LR, Tong ML, Fu ZG, Dan B, Zheng WH, Zhang CG, et al. (2011). Evaluation of a
colloidal gold immunochromatography assay in the detection of *Treponema pallidum* specific IgM antibody in syphilis serofast reaction patients: a serologic marker for the relapse and infection of syphilis. *Diagn Microbiol Infect Dis*, 70:10-16.

16. Dionne-Odom J, Karita E, Kilembe W, Henderson F, Vwalika B, Bayingana R, et al. (2013). Syphilis treatment response among HIV-discordant couples in Zambia and Rwanda. *Clin Infect Dis*, 56(12):1829-37.

17. Yang WL, Yang J, Huang XY (2005). Clinical analysis of seroresistance of syphilis in the past decade. *J Clin Dermato(China)*, 34(11):719-721.

18. Wang LN, Zuo YG, Liu YX, Liu XR, Zheng HY (2008). Incidence of seroresistance of syphilis and its relevant factors. *Acta Academiae Medicinae Sinicae* (China), 30(3): 338-341.

19. Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*, 6(7):e1000097.

20. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.

21. Wang X, Wang XQ (2012). Assessment of the quality of observational studies. *Chinese Journal of Clinical Nutrition (China)*, 20(5):330-331.

22. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. *Stat Med*, 21:1539-1558.

23. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. *Control Clin Trials*, 7: 177-188.

24. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. *BMJ*, 315: 629-634.

25. Zheng HG, Xie XL, Guo ED, Lian SH (2008). Clinical analysis of serofast patients. *Chin J Derm Venereol (China)*, 22(12):735-736.

26. Wu WQ, Huang ZY (2009). Clinical analysis of serum-resistance of syphilis. *Modern Preventive Medicine (China)*, 36(10):3156-3160.

27. Li J, Wang LN, Zuo YG, Liu YX, Liu XR, Lei Y, et al. (2009). Clinical analysis and study of immunological function in syphilis patients with seroresistance. *Zhonghua Yi Xue Za Zhi (China)*, 89(12):813-6.

28. Li ZG, Zeng RS (2010). Clinical analysis of serofast state after treatment among syphilitic patients. *Diagn Ther Derma Venereol (China)*, 17(3):204-206.

29. Yang WL, Lin WS, Yang J, Zheng HP (2011). Relationship between seroresistance and molecular subtypes of *Treponema pallidum* repeat gene. *Chinese Journal of Modern Medicine (China)*, 21(16):1821-1825.

30. Ying ZL, Wang F (2012). Clinical analysis of serofast patients among patients with syphilis. *J Dermatol and Venereology (China)*, 34(2):106-110.

31. Yang RD, Cai CC, Tian GN, He WQ, Zhang WJ, Lin SY, et al. (2005). Comparative study on peripheral blood lymphocyte subsets between untreated and serofast patients with syphilis. *Chin J Dermato Venereol Integ Trad W Med(China)*, 4(1):15-17.

32. Bao TY, Yu NS, Zeng K, Li L, Fang I (2006). Cellular immunity in patients with seroresistance of syphilis. *Practical Preventive Medicine (China)*, 13(2): 254-256.

33. Huang J, Lai WZ, Han HX, Zhang Y, Chen QF (2007). Effects of BCG-PSN on the T lymphocyte subsets in peripheral blood of patients with sero-resistance of syphilis. *Hainan Medicine (China)*, 18(7):17-18.

34. Liu OG, Huang QS, Chen Y, Jiang MY, Liang BH, Zeng MF (2007). Exploration of the relationship between the levels of IFN-γ, IL-10 and the seroresistant form of syphilis. *Chin J Derm Venereol(China)*, 21(7):416-417.

35. Liu JH, Han JD, Chen MK, Liao YM, Chen XH (2008). Comparative study of immunological function in syphilis patients with serum fixation and in patients with negative conversion after treatment. *Chin J AIDS STD(China)*, 14(4):385-386.

36. Bao TY, Yu NS, Zeng K (2008). Detection of the levels of IL-12, IL-10 in the serum among serofast patients with syphilis. *Chin J Misdag(China)*, 8(36):8845-8846.

37. Huang J (2008). Detection of peripheral blood lymphocyte subsets in early sero-resistance syphilis. *Chin J Derm Venereol(China)*, 22(9):546-547.

38. Chen X, Ye HJ, Zhao JP, Weng RQ (2010). Detection of IL-2, IL-10 among serofast patients from population with early syphilis and its significance. *Chin J Traid West Clin(China)*, 10(6):69.

39. Ling X, Liu RQ, Shi X, Ji SP, Sun XD, Ji J (2010).
Determination of Peripheral Blood Lymphocyte Subsets in Syphilitics of Serofast and Nerosyphilis and its Significance. Chin J Derm Venereol(China), 24(5):418-420.

40. Liu JL, Hu B, Zhao ZL, Zhang SP, Wu AL, Jiang FX (2010). Causes and correlative factors of serum-resistance of syphilis. Anhui Medical and Pharmaceutical Journal(China), 14(6):658-659.

41. Sun SB, Ou JM, Zhuang CM (2012). Expression and clinical significance of CD4+CD25+ regulatory T cells and interleukin-17 in peripheral blood of patients with sero-resistance of syphilis. J Diagn Ther Dermato Venereol(China), 19(1):19-21.

42. Zhang ZY, Li YS, Zhang XL, Ran LZ, Lin DZ (2012). Study on cellular immunity in pregnant women infected with syphilis undergoing sero-resistance after delivery. Guangxi Medical Journal(China), 34(5):546-548.

43. Lin YJ, Lin ME, Zheng DC, Lin W, Cai LH (2013). Relationship between regulatory T Cells, the Levels of IFN-γ, IL-10 and the sero-resistant syphilis. Chinese Journal of Human Sexuality(China), 22(7):30-36.

44. Xie HL, Zhao J, Li W, Gu GL, Huang PY, Lu JQ (2013). The detection of interleukins levels in peripheral blood of serofast syphilis patients. Chin J Derm Venereol(China), 27(5):485-501.

45. Xie HL, Zhao J, Li W, Gu GL, Liang FX, Li SY (2013). The detection of cellular immunity of seroresistance syphilis patients. Chin J Derm Venereol(China), 27(1):49-51.

46. Zhang CY (2013). Clinical analysis of serofast patients among syphilitic patients. Lab Med Clin(China), 10(7):887-888.

47. Liao YX (2011). Serofast or sero-resistance of syphilis. J Diagn Ther Dermato Venereol(China), 8(1):4-6.

48. Todd J, Munguti K, Grosskurth H, Mngara J, Changalucha J, Mayaud P, et al. (2001). Risk factors for active syphilis and TPHA seroconversion in a rural African population. Sex Transm Infect, 77:37-45.

49. Romanowski B, Sutherland R, Fick GH, Mooney D, Love EJ (1991). Serologic response to treatment of infectious syphilis. Ann Intern Med, 114:1005-9.

50. Leader BT, Hevner K, Molini BJ, Barrett LK, Van Voorhis WC, Lukehart SA (2003). Antibody responses elicited against the Treponema pallidum repeat proteins differ during infection with different isolates of Treponema pallidum subsp. pallidum. Infect Immun, 71(10):6054-6057.

51. Morgan CA, Lukehart SA, Van Voorhis WC (2003). Protection against syphilis correlates with specificity of antibodies to the variable regions of Treponema pallidum repeat protein K. Infect Immun, 71(10):5605-12.